413 related articles for article (PubMed ID: 20206139)
61. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
62. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
63. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
64. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
65. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
66. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).
Theobald DS; Maurer HH
Biochem Pharmacol; 2007 Jan; 73(2):287-97. PubMed ID: 17067556
[TBL] [Abstract][Full Text] [Related]
67. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
68. Recovery of dimethylnitrosamine-induced immunosuppression by pargyline in the mixed cultures of murine hepatocytes and splenocytes.
Jeong TC; Yang KH; Holsapple MP
Life Sci; 1994; 54(9):605-13. PubMed ID: 8114614
[TBL] [Abstract][Full Text] [Related]
69. CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells.
Molden E; Asberg A; Christensen H
Eur J Clin Pharmacol; 2000 Nov; 56(8):575-9. PubMed ID: 11151747
[TBL] [Abstract][Full Text] [Related]
70. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
71. Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528.
Kotsuma M; Tokui T; Freudenthaler S; Nishimura K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):545-55. PubMed ID: 19000552
[TBL] [Abstract][Full Text] [Related]
72. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
[TBL] [Abstract][Full Text] [Related]
73. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
DeVane CL; Markowitz JS; Carson SW; Boulton DW; Gill HS; Nahas Z; Risch SC
J Clin Psychopharmacol; 2000 Jun; 20(3):347-9. PubMed ID: 10831022
[TBL] [Abstract][Full Text] [Related]
74. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.
Takashima T; Murase S; Iwasaki K; Shimada K
Drug Metab Pharmacokinet; 2005 Jun; 20(3):177-82. PubMed ID: 15988119
[TBL] [Abstract][Full Text] [Related]
76. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.
Fasinu PS; Tekwani BL; Avula B; Chaurasiya ND; Nanayakkara NP; Wang YH; Khan IA; Walker LA
Malar J; 2016 Sep; 15(1):466. PubMed ID: 27618912
[TBL] [Abstract][Full Text] [Related]
77. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement.
Somogyi AA; Menelaou A; Fullston SV
Xenobiotica; 2004 Oct; 34(10):875-87. PubMed ID: 15764408
[TBL] [Abstract][Full Text] [Related]
78. Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.
Sangar MC; Anandatheerthavarada HK; Tang W; Prabu SK; Martin MV; Dostalek M; Guengerich FP; Avadhani NG
FEBS J; 2009 Jul; 276(13):3440-53. PubMed ID: 19438707
[TBL] [Abstract][Full Text] [Related]
79. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
80. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
